Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 01/2017, Volume 45, Issue 1, pp. 160 - 168
Summary Background In HCV‐infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the...
STORM | METAANALYSIS | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | PHARMACOLOGY & PHARMACY | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Follow-Up Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Interferons - therapeutic use | Neoplasm Recurrence, Local - surgery | Carcinoma, Hepatocellular - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Databases, Factual | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Carcinoma, Hepatocellular - diagnosis | Liver Neoplasms - drug therapy | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Neoplasm Recurrence, Local - diagnosis | Catheter Ablation - methods | Hepatitis C - diagnosis | Hepatitis C - surgery | Liver Neoplasms - diagnosis | Liver Cirrhosis - surgery | Aged | Care and treatment | Ablation (Surgery) | Usage | Relapse | Liver | Hepatoma | Biological response modifiers | Diseases | Analysis | Surgery | Interferon | Hepatitis C virus | Liver cirrhosis | Cirrhosis | Liver cancer | Antiviral agents | Documents | Hepatocellular carcinoma | Infections | Ablation | Patients | Cancer | Tumors
STORM | METAANALYSIS | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | PHARMACOLOGY & PHARMACY | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Follow-Up Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Interferons - therapeutic use | Neoplasm Recurrence, Local - surgery | Carcinoma, Hepatocellular - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Databases, Factual | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Carcinoma, Hepatocellular - diagnosis | Liver Neoplasms - drug therapy | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Neoplasm Recurrence, Local - diagnosis | Catheter Ablation - methods | Hepatitis C - diagnosis | Hepatitis C - surgery | Liver Neoplasms - diagnosis | Liver Cirrhosis - surgery | Aged | Care and treatment | Ablation (Surgery) | Usage | Relapse | Liver | Hepatoma | Biological response modifiers | Diseases | Analysis | Surgery | Interferon | Hepatitis C virus | Liver cirrhosis | Cirrhosis | Liver cancer | Antiviral agents | Documents | Hepatocellular carcinoma | Infections | Ablation | Patients | Cancer | Tumors
Journal Article
PLoS Medicine, ISSN 1549-1277, 04/2016, Volume 13, Issue 4, p. e1002006
Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as...
AMBULATORY PATIENTS | MEDICINE, GENERAL & INTERNAL | LIVER-TRANSPLANTATION | STAGING-SYSTEM | PERFORMANCE | CLASSIFICATION | PROPOSAL | MODEL | MILAN CRITERIA | CANCER | ESTIMATE SURVIVAL | Predictive Value of Tests | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Carcinoma, Hepatocellular - secondary | Neoplasms, Multiple Primary | Liver Neoplasms - mortality | alpha-Fetoproteins - analysis | Liver Neoplasms - blood | Neoplasm Staging - methods | Time Factors | Female | Liver Neoplasms - pathology | Retrospective Studies | Carcinoma, Hepatocellular - blood | Databases, Factual | Reproducibility of Results | Risk Assessment | Neoplasm Invasiveness | Risk Factors | Decision Support Techniques | Tumor Burden | Survival Analysis | Taiwan | Italy | Aged | Care and treatment | Glycoproteins | Metastasis | Hepatoma | Analysis | Liver | Physiological aspects | Prognosis | Research | Liver cancer | Researchers | Medical prognosis | Calibration | Liver cirrhosis | Data bases | Manuscripts
AMBULATORY PATIENTS | MEDICINE, GENERAL & INTERNAL | LIVER-TRANSPLANTATION | STAGING-SYSTEM | PERFORMANCE | CLASSIFICATION | PROPOSAL | MODEL | MILAN CRITERIA | CANCER | ESTIMATE SURVIVAL | Predictive Value of Tests | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Carcinoma, Hepatocellular - secondary | Neoplasms, Multiple Primary | Liver Neoplasms - mortality | alpha-Fetoproteins - analysis | Liver Neoplasms - blood | Neoplasm Staging - methods | Time Factors | Female | Liver Neoplasms - pathology | Retrospective Studies | Carcinoma, Hepatocellular - blood | Databases, Factual | Reproducibility of Results | Risk Assessment | Neoplasm Invasiveness | Risk Factors | Decision Support Techniques | Tumor Burden | Survival Analysis | Taiwan | Italy | Aged | Care and treatment | Glycoproteins | Metastasis | Hepatoma | Analysis | Liver | Physiological aspects | Prognosis | Research | Liver cancer | Researchers | Medical prognosis | Calibration | Liver cirrhosis | Data bases | Manuscripts
Journal Article
International Journal of Drug Policy, ISSN 0955-3959, 09/2018, Volume 59, pp. 50 - 53
People who are incarcerated have a significantly higher prevalence of HCV infection than the general population. Given their high-risk behavior, they represent...
Prison settings | Inmates | Direct acting antivirals | Hepatitis C virus | PRISONERS | METAANALYSIS | HIV | PREVENTION | SUBSTANCE ABUSE | HEPATITIS-C | Medical research | Antiviral agents | Communicable diseases | Liver | HIV (Viruses) | Prisons | Highly active antiretroviral therapy | Medicine, Experimental | Reservoirs | Hepatitis C | Health aspects | Liver cirrhosis
Prison settings | Inmates | Direct acting antivirals | Hepatitis C virus | PRISONERS | METAANALYSIS | HIV | PREVENTION | SUBSTANCE ABUSE | HEPATITIS-C | Medical research | Antiviral agents | Communicable diseases | Liver | HIV (Viruses) | Prisons | Highly active antiretroviral therapy | Medicine, Experimental | Reservoirs | Hepatitis C | Health aspects | Liver cirrhosis
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 11, pp. 1927 - 1933.e2
Background & Aims Ultrasound surveillance does not detect early stage hepatocellular carcinomas (HCCs) in some patients with cirrhosis, although the reasons...
Gastroenterology and Hepatology | Early Detection | Liver Cancer | Survival | Fibrosis | UNITED-STATES | TRIAL | DIAGNOSIS | SEMIANNUAL SURVEILLANCE | HEPATITIS-C VIRUS | GASTROENTEROLOGY & HEPATOLOGY | ALPHA-FETOPROTEIN | Carcinoma, Hepatocellular - diagnosis | Liver Cirrhosis - complications | Humans | Middle Aged | Male | Liver Neoplasms - diagnosis | Diagnostic Tests, Routine - methods | Sensitivity and Specificity | Aged, 80 and over | Adult | Female | Italy | Aged | Retrospective Studies | Ultrasonography - methods
Gastroenterology and Hepatology | Early Detection | Liver Cancer | Survival | Fibrosis | UNITED-STATES | TRIAL | DIAGNOSIS | SEMIANNUAL SURVEILLANCE | HEPATITIS-C VIRUS | GASTROENTEROLOGY & HEPATOLOGY | ALPHA-FETOPROTEIN | Carcinoma, Hepatocellular - diagnosis | Liver Cirrhosis - complications | Humans | Middle Aged | Male | Liver Neoplasms - diagnosis | Diagnostic Tests, Routine - methods | Sensitivity and Specificity | Aged, 80 and over | Adult | Female | Italy | Aged | Retrospective Studies | Ultrasonography - methods
Journal Article
Liver International, ISSN 1478-3223, 08/2017, Volume 37, Issue 8, pp. 1157 - 1166
Background & Aims Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)‐related...
recurrences | prognosis | hepatocellular carcinoma | survival | OXIDATIVE STRESS | ANGIOGENESIS | RNA REPLICATION | LIVER-DISEASES | MECHANISMS | ANGIOPOIETIN-2 | CORE PROTEIN | NS5A PROTEIN INTERACTS | HEPATITIS-C VIRUS | ENDOTHELIAL-CELLS | GASTROENTEROLOGY & HEPATOLOGY | Liver Neoplasms - virology | Carcinoma, Hepatocellular - mortality | Humans | Hepatitis C - complications | Carcinoma, Hepatocellular - therapy | Carcinoma, Hepatocellular - virology | Liver Neoplasms - therapy | Neoplasm Recurrence, Local - epidemiology | Liver Neoplasms - mortality | Antiviral agents | Care and treatment | Ablation (Surgery) | Analysis | Mortality | Albumin | Hepatoma | Hepatitis C virus | Hepatitis C | Health aspects | Identification methods | Clinical trials | Viruses | Hepatocellular carcinoma | Serum albumin | Regression analysis | Risk analysis | α-Fetoprotein | Ablation | Patients | Survival | Studies | Hepatitis | Heterogeneity | Liver cancer | Randomization | Tumors
recurrences | prognosis | hepatocellular carcinoma | survival | OXIDATIVE STRESS | ANGIOGENESIS | RNA REPLICATION | LIVER-DISEASES | MECHANISMS | ANGIOPOIETIN-2 | CORE PROTEIN | NS5A PROTEIN INTERACTS | HEPATITIS-C VIRUS | ENDOTHELIAL-CELLS | GASTROENTEROLOGY & HEPATOLOGY | Liver Neoplasms - virology | Carcinoma, Hepatocellular - mortality | Humans | Hepatitis C - complications | Carcinoma, Hepatocellular - therapy | Carcinoma, Hepatocellular - virology | Liver Neoplasms - therapy | Neoplasm Recurrence, Local - epidemiology | Liver Neoplasms - mortality | Antiviral agents | Care and treatment | Ablation (Surgery) | Analysis | Mortality | Albumin | Hepatoma | Hepatitis C virus | Hepatitis C | Health aspects | Identification methods | Clinical trials | Viruses | Hepatocellular carcinoma | Serum albumin | Regression analysis | Risk analysis | α-Fetoprotein | Ablation | Patients | Survival | Studies | Hepatitis | Heterogeneity | Liver cancer | Randomization | Tumors
Journal Article
The International Journal on Drug Policy, ISSN 0955-3959, 09/2018, Volume 59, p. 50
Background People who are incarcerated have a significantly higher prevalence of HCV infection than the general population. Given their high-risk behavior,...
Intervention | Drugs | High risk | Liver diseases | Risk behavior | Demographic aspects | Liver | Critical incidents | Inmates of institutions | Males | Patients | Antiretroviral therapy | Clinical outcomes | Prisons | Infection | Hepatitis | Ex-prisoners | Treatment | Human immunodeficiency virus--HIV | Men | Hepatitis C | Antiviral drugs | Release | Prisoners
Intervention | Drugs | High risk | Liver diseases | Risk behavior | Demographic aspects | Liver | Critical incidents | Inmates of institutions | Males | Patients | Antiretroviral therapy | Clinical outcomes | Prisons | Infection | Hepatitis | Ex-prisoners | Treatment | Human immunodeficiency virus--HIV | Men | Hepatitis C | Antiviral drugs | Release | Prisoners
Journal Article
Journal of Chemotherapy, ISSN 1120-009X, 01/2019, Volume 31, Issue 1, pp. 9 - 14
Skin and soft tissue infections (SSTIs) represent a wide range of clinical conditions characterized by a considerable variety of clinical presentations and...
microbiology | registry | skin and soft tissue infections | Epidemiology | DIAGNOSIS | INFECTIOUS DISEASES | MANAGEMENT | SOCIETY | DISEASES | ONCOLOGY | PHARMACOLOGY & PHARMACY | CONSENSUS STATEMENT | DEEP TISSUE
microbiology | registry | skin and soft tissue infections | Epidemiology | DIAGNOSIS | INFECTIOUS DISEASES | MANAGEMENT | SOCIETY | DISEASES | ONCOLOGY | PHARMACOLOGY & PHARMACY | CONSENSUS STATEMENT | DEEP TISSUE
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 02/2016, Volume 43, Issue 3, pp. 385 - 399
Summary Background Hepatitis C virus (HCV) and alcohol abuse are the main risk factors for hepatocellular carcinoma (HCC) in Western countries. Aim To...
IMPACT | RISK-FACTORS | EARLY-DIAGNOSIS | CHRONIC LIVER-DISEASE | CIRRHOSIS | GROWTH-RATE | SURVEILLANCE | PHARMACOLOGY & PHARMACY | LEAD-TIME | GASTROENTEROLOGY & HEPATOLOGY | COMPUTED-TOMOGRAPHY | ALPHA-FETOPROTEIN | Carcinoma, Hepatocellular - mortality | Prognosis | Age Factors | Humans | Middle Aged | Male | Liver Neoplasms - mortality | Esophageal and Gastric Varices - epidemiology | Liver Neoplasms - etiology | Hepatitis, Alcoholic - epidemiology | Hepatitis, Alcoholic - physiopathology | Hepatitis C - epidemiology | Aged, 80 and over | Female | Hepatitis C - complications | Carcinoma, Hepatocellular - etiology | Retrospective Studies | alpha-Fetoproteins - metabolism | Liver Function Tests | Risk Factors | Proportional Hazards Models | Treatment Outcome | Hepatitis, Alcoholic - complications | Venous Thrombosis - epidemiology | Sex Factors | Hepatitis C - physiopathology | Aged | Neoplasm Staging | Care and treatment | Alcoholism | Liver | Glycoproteins | Substance abuse | Hepatoma | Hepatitis C virus | Health aspects
IMPACT | RISK-FACTORS | EARLY-DIAGNOSIS | CHRONIC LIVER-DISEASE | CIRRHOSIS | GROWTH-RATE | SURVEILLANCE | PHARMACOLOGY & PHARMACY | LEAD-TIME | GASTROENTEROLOGY & HEPATOLOGY | COMPUTED-TOMOGRAPHY | ALPHA-FETOPROTEIN | Carcinoma, Hepatocellular - mortality | Prognosis | Age Factors | Humans | Middle Aged | Male | Liver Neoplasms - mortality | Esophageal and Gastric Varices - epidemiology | Liver Neoplasms - etiology | Hepatitis, Alcoholic - epidemiology | Hepatitis, Alcoholic - physiopathology | Hepatitis C - epidemiology | Aged, 80 and over | Female | Hepatitis C - complications | Carcinoma, Hepatocellular - etiology | Retrospective Studies | alpha-Fetoproteins - metabolism | Liver Function Tests | Risk Factors | Proportional Hazards Models | Treatment Outcome | Hepatitis, Alcoholic - complications | Venous Thrombosis - epidemiology | Sex Factors | Hepatitis C - physiopathology | Aged | Neoplasm Staging | Care and treatment | Alcoholism | Liver | Glycoproteins | Substance abuse | Hepatoma | Hepatitis C virus | Health aspects
Journal Article
Liver International, ISSN 1478-3223, 03/2017, Volume 37, Issue 3, pp. 423 - 433
Background & Aims The Barcelona Clinic Liver Cancer intermediate stage (BCLC‐B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in...
intermediate stage | treatment | HCC | BCLC‐B | BCLC-B | CRITERIA | LIVER-TRANSPLANTATION | MANAGEMENT | SURVIVAL BENEFIT | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION | GUIDELINES | BCLC STAGE | RECOMMENDATIONS | EXPERIENCE | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-PRACTICE | Niacinamide - analogs & derivatives | Multivariate Analysis | Standard of Care | Chemoembolization, Therapeutic | Humans | Middle Aged | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Liver Neoplasms - therapy | Patient Selection | Propensity Score | Survival Analysis | Female | Italy - epidemiology | Aged | Carcinoma, Hepatocellular - therapy | Retrospective Studies | Neoplasm Staging | Hepatoma | Mortality | Analysis | Liver | Liver cancer | Hepatocellular carcinoma | Patients | Tumors
intermediate stage | treatment | HCC | BCLC‐B | BCLC-B | CRITERIA | LIVER-TRANSPLANTATION | MANAGEMENT | SURVIVAL BENEFIT | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION | GUIDELINES | BCLC STAGE | RECOMMENDATIONS | EXPERIENCE | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-PRACTICE | Niacinamide - analogs & derivatives | Multivariate Analysis | Standard of Care | Chemoembolization, Therapeutic | Humans | Middle Aged | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Liver Neoplasms - therapy | Patient Selection | Propensity Score | Survival Analysis | Female | Italy - epidemiology | Aged | Carcinoma, Hepatocellular - therapy | Retrospective Studies | Neoplasm Staging | Hepatoma | Mortality | Analysis | Liver | Liver cancer | Hepatocellular carcinoma | Patients | Tumors
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 01/2016, Volume 111, Issue 1, pp. 70 - 77
OBJECTIVES: The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma...
SYSTEM | ONCOLOGY-GROUP | MANAGEMENT | PROGNOSIS | SURVIVAL ANALYSIS | CIRRHOSIS | GUIDELINES | VALIDATION | SURVEILLANCE | GASTROENTEROLOGY & HEPATOLOGY | BCLC-B | Liver Neoplasms - classification | Prognosis | Prospective Studies | Humans | Middle Aged | Male | Young Adult | Carcinoma, Hepatocellular - pathology | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Aged | Neoplasm Staging | Carcinoma, Hepatocellular - classification
SYSTEM | ONCOLOGY-GROUP | MANAGEMENT | PROGNOSIS | SURVIVAL ANALYSIS | CIRRHOSIS | GUIDELINES | VALIDATION | SURVEILLANCE | GASTROENTEROLOGY & HEPATOLOGY | BCLC-B | Liver Neoplasms - classification | Prognosis | Prospective Studies | Humans | Middle Aged | Male | Young Adult | Carcinoma, Hepatocellular - pathology | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Aged | Neoplasm Staging | Carcinoma, Hepatocellular - classification
Journal Article